SAGE Description — Sage Therapeutics Inc

Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines with the potential to transform the lives of people with debilitating disorders of the brain. Co.'s principal product, ZULRESSO, is a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. Co.'s other product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder, and PPD. Co. has a portfolio of other compounds that target GABAA receptors, including SAGE-324. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing.

Company Name: 
Sage Therapeutics Inc
Drugs & Pharmaceuticals
Number of ETFs Holding SAGE: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   SAGE Weight   SAGE Amount 
 XBI   1.01%   $66,533,487         
 VTI   0.01%   $65,479,490         
 VB   0.05%   $54,807,493         
 IWM   0.10%   $48,912,507         
 VBK   0.11%   $31,676,941         
 VXF   0.04%   $29,328,734         
 IWN   0.20%   $22,106,094         
 VHT   0.04%   $7,746,315         
 VTWO   0.10%   $5,861,626         
 ITOT   0.01%   $2,181,403         
List of all 28 ETFs holding SAGE »
Quotes delayed 20 minutes

Email EnvelopeFree SAGE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (2.82 out of 4)
17th percentile
(ranked lower than approx. 83% of all stocks covered)

Analysts Forecast:
SAGE Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding SAGE | Sage Therapeutics Inc | ETF Channel |

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.